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Abstract
Endogenous lectins play key roles in cell homeostasis by decoding 
the information encrypted in glycans present on the cell surface 
or extracellular matrix. Galectins, a family of soluble lectins, have 
emerged as central regulators of innate and adaptive immune 
responses. In this article, we review seminal work demonstrating 
the immunoregulatory roles of Galectin-1 (Gal-1), a proto-type 
member of the galectin family, and highlight central mechanisms 
that control its functions in cancer and autoimmune inflammation. 
Understanding the cellular pathways that control Gal-1 expression 
and function in tumor and inflammatory microenvironments will set the bases for the design of rational 
therapies based on positive or negative modulation of this endogenous lectin in cancer and autoimmune 
diseases.
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Introduction: The Cellular Glycome
Every cell, from bacteria to neurons or lymphocytes, displays saccharide structures (glycans) covalently linked to proteins 
and lipids on the cellular surface. Glycans play crucial roles in several biological processes, such as cellular migration, 
differentiation, communication, immunity, and vascularization [1–4]. Our immune system harnesses the vast amount 
of information stored in glycan structures to control its activation, differentiation, and homeostasis [5]. Glycans are 
hierarchically assembled in proteins and lipids through the coordinated action of glycosyltransferases and glycosidases. In 
mammals, protein glycosylation occurs in parallel to protein synthesis in the endoplasmic reticulum, and then continues 
in the Golgi apparatus. To decipher the information encoded by glycoconjugates, dedicated glycan-binding proteins are 
required, which trigger distinct signaling pathways to modulate cell fate and function.
In the era of multi-omics, “glycomics” arises as a major challenge being tackled by scientists from different 
backgrounds and disciplines. Studying the structure, functions, and synthesis of lectins and glycans is the main goal of 
Glycobiology. Due to the high combinatorial possibilities of glycans present in cells and tissues, these structures emerge 
as a major source of biological information and diversity. This feature makes glycoconjugates attractive therapeutic 
targets and biomarkers in several pathologic conditions. First, their location on the cell surface makes them the first 
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contact point during cellular communication, thus operating as central regulators of a diversity of metabolic processes 
and host-pathogen interactions [6]. Second, specific glycan structures that are absent or are present in very low amounts in 
steady-state conditions can increase in proportion or alter their composition under stress or pathologic situations. Finally, 
lectin-glycan interactions may trigger, aggravate, or ameliorate pathological conditions by recalibrating immune cell 
homeostasis and rewiring signaling pathways in several cell types.
Glycosylation pathways and glycan-binding proteins
There are two major glycosylation pathways, namely N- and O-glycosylation (Figure 1). The prevalence of each individual 
pathway relies on several factors, including cell type and its physiologic activation, differentiation, and nutritional 
state. Furthermore, epigenetic regulation of glycosyltransferases and glycosidases, subcellular compartmentalization of 
individual components of the glycosylation machinery and nucleotidic sugar availability are also critical factors that 
affect the abundance of different glycans [7]. The presence of N- and O-glycans on a given cell type also depends on 
dynamic parameters of individual microenvironments including the oxygen levels, nutrient availability and prevalence 
of particular growth factors and cytokines. In this regard, a complex interplay occurs between the glycosylation profile 
of a given cell type and the development of particular disease states, highlighting the importance of studying the cellular 
glycome under physiologic and pathologic conditions [1]. In fact, particular glycosylation profiles have been associated 
with pathologic processes including chronic inflammation [8–10] and cancer [11,12].
The myriad of possible glycan combinations that can arise as a consequence of the coordinated action of 
glycosyltransferases and glycosidases has been shown to provide a valuable source of information that governs cell 
processes, including proliferation, survival, activation, differentiation, and migration [1]. N-glycosylation involves the 
addition of glycans on an asparagine residue within a consensus region -N-X-S/T, where X cannot be proline. This process 
involves sequential modification of an initial mannose-rich glycan by glycosidases and glycosyltransferases. Of particular 
interest for this review are N-acetylglucosaminyltransferases (MGAT1, 2, 4, and 5) that play critical roles as they generate 
the N-acetylglucosaminyl branches that serve as permissive sites for further extension of N-acetyl-lactosamine (Galβ1-
4GlcNAc; LacNAc) structures, which are the main target for galectins [13,14]. Furthermore, α2,6-sialyltransferase 1 
(ST6Gal-1), an enzyme that incorporates sialic acid to complex N-glycans in an α2,6-linked position, inhibits binding of 
specific galectins (particularly Gal-1) to N-glycan structures. On the other hand, O-glycosylation occurs later, inside the 
Golgi apparatus, on serine or threonine residues, with T-synthase (C1GALT1) being critical for the formation of core-
1-O-glycans and α2,3-sialyltransferase (ST3Gal-1) further adding sialic acid to the galactose residue within the same 
structure [4].
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Figure 1. Glycosylation pathways involved in the synthesis of galectin ligands. The figure shows a summary of the main 
protein glycosylation pathways: N- and O-glycosylation and Gal-1 binding sites. Created with BioRender.com.
The responsibility of decoding the biologic information encrypted by glycans relies on endogenous glycan-binding 
proteins or lectins. Lectins are capable of recognizing complex glycosidic structures on the surface of proteins and lipids 
and triggering different cellular responses. The magnitude and quality of these responses ultimately rely on the multivalent 
nature of lectin-glycan interactions [15,16]. Several studies have shown, using computational modeling and biophysical 
approaches, that lectin-glycan interactions can lead to the formation of complex multivalent structures, often termed 
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“lattices”, on the surface of different cell types [16]. These structures may be assembled into supramolecular domains 
on the cell surface leading to glycoprotein segregation and control of signaling threshold, activation, and endocytosis of 
cell surface receptors [17]. In several cases, these lectin-glycan complexes may substitute canonical ligands and activate 
surface receptors, triggering vital biologic responses such as activation, differentiation and survival [18]. Within the 
immune system, three major families of lectins play crucial stimulatory or inhibitory roles: a) C-type lectin receptors 
(CLRs); b) Sialic acid-binding immunoglobulin-type lectins (Siglecs) and c) galectins [9,10,12].
CLRs comprise a heterogeneous family of calcium ion-dependent lectins subdivided into two distinct categories based 
on the presence of an amino acidic motif involved in glycan recognition and calcium coordination. Most of these lectins 
possess one or more carbohydrate recognition domains (CRDs) and are present on the surface of many immune cell 
types, such as macrophages and dendritic cells (DCs). CLRs containing the amino acid motif EPN (Glu-Pro-Asn) have an 
affinity for glycans containing mannose or fucose. This subgroup includes DC-Specific Intercellular adhesion molecule-
3-Grabbing Non-integrin (DC-SIGN), the mannose receptor (MR), and Langerin. The other is composed of CLRs 
containing the QPD motif (Gln-Pro-Asp), which interacts specifically with N-acetyl-galactosamine present in the terminal 
position of glycans. MGL receptor (Macrophage Galactose-type Lectin), present in macrophages and DCs, is an example 
of this subgroup of CRLs [19]. It is worth mentioning that some CLRs do not have the Ca2+ requirement to interact with 
glycans, such as the Dectin-1 receptor that specifically recognizes β-glucans in yeasts [20]. The interaction between many 
specific CLRs and glycans leads to ligand internalization by endocytosis, followed by intracellular signaling pathways 
that lead to the expression of innate immunity-related genes [21]. Thus, CLRs are key lectins that participate in the innate 
immune response to bacterial and fungal infections, among other functions. 
Siglecs are a family of lectins that have specificity for glycans containing sialic acid. Some of them have a restricted 
expression pattern, such as Siglec-2 (CD22) that is preferentially found on B cells, while others are expressed in several 
hematopoietic lineage cells, like B lymphocytes, macrophages, and eosinophils. To date, 16 Siglecs have been identified in 
humans, showing a variable number of immunoglobulin-like domains ranging from 2 in Siglec-3 (CD33) to 17 in Siglec-1 
(Sialoadhesin, CD169) and slight differences in sialoside preferences. Several members of this family are relevant in 
many infectious diseases (e.g. HIV-1 and Group B Streptococcus infections), autoimmune diseases (e.g. rheumatoid 
arthritis), cancer (e.g. leukemia, lymphoma) and neurological diseases (e.g. Alzheimer disease) [6]. Recognition of sialic 
acid by siglecs usually promotes phosphorylation of the cytoplasmic ITIM motifs and further recruitment of phosphatases 
from the SHP family, which in turn inhibit diverse cell events including activation, signaling and proliferation [22]. 
While CLRs and siglecs act primarily as transmembrane proteins present on the surface of immune cells, galectins are 
soluble proteins secreted into the extracellular medium via a non-canonical secretory pathway (without involvement of the 
ER-Golgi system). Once in the extracellular space, galectins interact with a wide variety of glycosylated receptors through 
protein-glycan and protein-protein interactions, in a broad spectrum of cell types [10,12]. Intracellularly, galectins can 
modulate signaling pathways, control lymphocyte survival, and even interact with the RNA splicing machinery [10,23–
26]. Fifteen members of the galectin family are known in mammals, although galectin-like domains have been identified 
in insects, fungi and plants [25], [27]. Galectins have at least one CRD of approximately 130 structurally-preserved amino 
acids and can be subdivided into three subgroups based on their structural features: a) “Proto-type” galectins (Gal-1, -2, 
-5, -7, -10, -11, -13, -14, and -15) have a single CRD and can be found as monomers or dimers; b) “Tandem repeat-type” 
galectins (Gal-4, -6, -8, -9, and -12) contain two tandem CRDs within the same polypeptide chain, joined by a separating 
region (linker) of up to 70 amino acids and c) “Chimera-type” galectins have a single CRD and a non-lectin N-terminal 
region, necessary for its oligomerization, Gal-3 being the only member of this subgroup (Figure 2) [10, 25, 28]. 
Initially, galectins were defined by their ability to recognize the disaccharide LacNac present in N- and O-glycans on 
cell surface glycoproteins [29]. However, galectins’ CRDs can differ in some amino acids, which are not in the conserved 
sequence, leading to their ability to recognize different structures. Furthermore, modifications to the LacNAc or poly-
LacNAc structure can differentially affect galectin-glycan interactions. While some galectins tolerate the addition of a 
terminal sialic acid or internal fucose in the lactosamine sequence, others are not able to bind LacNac modified with these 
residues [30, 31]. In this regard, we have recently found that Gal-12, a lectin preferentially expressed by adipocytes, binds 
to 3’-fucosylated structures with high affinity, making it the first member of the galectin family showing specificity for 
this glycan structure [32]. Besides, galectins differ in their ability to recognize LacNAc in a terminal position or internal 
repetitions within the glycan structure (Figure 2). This relative selectivity could explain, at least in part, the functional 
differences observed among individual family members [29, 33–35]. Several factors can influence the biological activity 
of galectins including their oligomerization status, exposure of N- and O-glycans on target cells and the prevailing 
oxidative or reducing conditions of different tissue microenvironments [10]. While some galectins have a ubiquitous 
expression pattern, others exhibit a specific tissue distribution. Within the immune system, galectins are expressed by 
virtually all cells either constitutively or in an inducible manner [10, 15, 25, 28]. Furthermore, galectins can recognize 
glycans present on the surface of microorganisms, suggesting an early evolutionary origin for these molecules as soluble 
proteins capable of recognizing pathogen-associated glycosylated patterns [15, 36, 37].
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Figure 2. Classification of galectins: structure, function, and specificity. A- Figure shows a representation of the structure 
of the galectin family; B- Schematic representation of Gal-1 lattices upon trivalent glycan binding. C- Lattice formation 
gives rise to receptor clustering, activation triggering and altered internalization. Created with BioRender.com.
In the following sections, we will focus on seminal discoveries leading to the identification of central roles of Gal-1, 
crucial to immune tolerance and homeostasis in different physiopathologic conditions. We will discuss the therapeutic 
implications derived from the function of Gal-1 in chronic inflammation, vascularization, autoimmunity, pregnancy, and 
cancer, and will highlight some of the contributions of our group to understanding these conditions from a glycobiological 
perspective.
Gal-1: a novel mechanism of tumor-immune escape and therapeutic target in cancer
During the last decade, the revolution of cancer immunotherapies changed our perspective on how our immune system 
interacts with tumors. However, the idea of the immune system playing a pivotal role in tumor biology dates back to more 
than a century ago when William Coley used extracts of heat-inactivated S. pyogenes and S. marcescens (termed as the 
Coley toxin) to treat cancer patients seeking to enhance their immune response [38, 39]. In 1909, Paul Ehrlich came up 
with the idea that our immune system is continuously eliminating transformed cells that could potentially cause tumors 
[38, 40]. Back to our days, it is well established that a fully competent immune system, composed of a variety of cell 
types including natural killer (NK) cells, CD8+ cytotoxic T lymphocytes, CD4+ helper T lymphocytes, macrophages, 
DCs and others, can identify and destroy transformed cells in pre-neoplastic and neoplastic lesions. Nevertheless, either 
due to a generalized state of immunosuppression or to specific inhibitory mechanisms displayed within the local tumor 
microenvironment, cancer cells have the ability to evade innate and adaptive immune responses. In fact, many cancer 
cells co-opt immunoregulatory programs that are commonly activated during the physiologic resolution of inflammation 
to restore immune cell homeostasis. For example, the expression of Programmed Cell Death Ligand-1 (PD-L1) on 
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the surface of tumor cells dampens the activation and proliferation of T cells, fostering a dysfunctional state called T 
cell exhaustion, which compromises cytotoxic anti-tumor immunity favoring tumor growth [38]. Among the several 
mechanisms implicated in immune evasion, the upregulation of inhibitory molecules termed as “immune checkpoints”, 
such as the PD-1/PD-L1 axis and the cytotoxic T-lymphocyte antigen receptor (CTLA-4), stand out among the others due 
to their clinical and therapeutic relevance in a broad range of cancers [41–44]. 
Understanding the mechanisms underlying tumor-immune escape led to the development of a broad range of 
immunotherapeutic modalities seeking to reverse the immune inhibitory mechanisms triggered by tumors and boosting 
the immune system to control tumor growth and metastasis. In particular, monoclonal antibodies targeting the immune 
checkpoint pathways CTLA-4 and PD-1/PD-L1 have generated unprecedented clinical success and therapeutic 
opportunities to treat a wide variety of tumors including melanoma, lung adenocarcinoma, renal cancer, gastrointestinal 
tumors, head and neck squamous carcinoma, triple negative breast cancer, non-melanoma squamous cell carcinomas, 
Hodgkin’s lymphoma, and others. Moreover, other therapeutic approaches are based on agonist antibodies to co-
stimulatory molecules, tumor cell vaccines (like DC vaccines), or chimeric antigen receptors (CARs) [38]. Outstanding 
clinical benefits, including tumor size reduction and increased disease-free survival, have been observed in a large number 
of cancer patients receiving immunotherapy [41–45]. However, some patients are resistant to these treatments, either 
through intrinsic or acquired mechanisms, and experience a relapse characterized by tumor recurrence at the primary 
site or distant tissue outgrowth in a process known as metastasis [45, 46]. These compensatory mechanisms include the 
expression of alternative inhibitory molecules such as lymphocyte activation gene-3 (LAG-3) and T cell immunoglobulin 
mucin-3 (TIM-3), among others, whose autonomic functions can control various aspects of the anti-tumor immune 
response, promoting alternative escape pathways [47]. 
Our laboratory has focused on elucidating the immunoregulatory circuits triggered by Gal-1-glycan interactions in 
tumor and inflammatory microenvironments. Initially, we found that human and mouse melanoma cells secrete Gal-
1, which substantially contributes to the immune privilege of these tumors by regulating distinct immune effector 
mechanisms. Gal-1 silencing in the B16 melanoma mouse model resulted in heightened tumor rejection, increasing 
expansion of T helper (Th)1 and cytotoxic CD8+ T cells [48] (Figure 3). Investigation of the molecular mechanisms 
underlying Gal-1-driven immunoregulation revealed the ability of this lectin to induce selective apoptosis of cytotoxic 
CD8+ T cells, Th1, and Th17 lymphocytes, skipping Th2 and naiïve T cells [48] [49]. This differential susceptibility to 
cell death was associated with dissimilar sialylation patterns among distinct effector T cells. Whereas activated CD8+ T 
cells as well as Th1, and Th17 display all of the essential glycans that are critical for Gal-1 binding (high frequency of 
non-sialylated glycans and elongated LacNAc residues on core-2- O-glycan structures), Th2 lymphocytes as well as naïve 
T cells exhibit high frequency of α2,6 sialylation which prevents Gal-1 binding to terminal LacNAc residues [10, 49] 
(Figure 3). Interestingly, this tumor-immune privilege mechanism was also evident in classical Hodgkin’s lymphoma. 
In these tumors, Reed Sternberg cells up-regulate Gal-1 expression through the activation of an enhancer of the AP-1 
transcription factor driven by the Epstein Bar virus (EBV), thereby supporting the Th2-dominant immunosuppressive 
microenvironment typical of this hematologic malignancy [50]. Accordingly, Gal-1 has been identified as a biomarker 
of refractory/resistant disease in classical Hodgkin lymphoma patients [51]. Furthermore, Gal-1 silencing in the triple 
negative breast cancer mouse model 4T1 resulted in reduced tumor size and metastases, accompanied by lower frequency 
of regulatory T cells (Treg) in the tumor microenvironment, lymph nodes and metastatic lungs [52] (Figure 3). Thus, both 
tumor and associated stroma may express and secrete Gal-1, promoting the generation of an immunosuppressive milieu 
and the activation of tolerogenic circuits that thwart the development of effective anti-tumor T cell responses.
In addition to modulation of adaptive T-cell responses, Gal-1 also controls innate immune pathways by modulating 
macrophage and DC function. In this regard, we found that Gal-1 triggers an M2 macrophage profile by regulating 
L-arginine metabolism and interfering with major histocompatibility complex (MHC)-II-dependent antigen presentation 
as well as Fcγ receptor I-dependent phagocytosis [53, 54]. Furthermore, silencing of tumor-derived-Gal-1 by short-
hairpin RNA (shRNA) in the high-grade glioma mouse model GL261 decreased myeloid cell accumulation within the 
tumor microenvironment and prolonged survival in tumor-bearing mice [55]. In addition, Gal-1 induced differentiation 
of tolerogenic DCs by regulating phosphorylation of the signal transducer and activator of transcription 3 (STAT3) 
transcription factor, and favoring the expression of anti-inflammatory cytokines including IL-27 and IL-10, which 
dampen anti-tumor responses [56]. In addition, Gal-1 secreted by mouse and human neuroblastoma cells triggers 
immunosuppressive programs by compromising T cell and DC functions [57] (Figure 3).
The expression of Gal-1 in several cancer types, including prostate, breast, lung and pancreatic cancer, increases 
with tumor progression, thus underlining a central role of this lectin as a possible prognostic biomarker of neoplastic 
progression and an attractive therapeutic target in a variety of cancer types [58–60]. In this context, we found that Gal-
1 exerts both paracrine and autocrine functions that control proliferation, anti-tumor immunity, and angiogenesis in 
pancreatic adenocarcinoma, thus reinforcing the multifunctional role of Gal-1 during tumor progression [60]. Supporting 
these observations, high levels of Gal-1 were associated with lower infiltration of cytotoxic CD8+ T cells and poor clinical 
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outcomes in T cell lymphomas [61]. Furthermore, Nambiar and colleagues recently reported a role for Gal-1 in resistance 
to immunotherapy in head and neck squamous cell carcinoma (HNSCC). Particularly, Gal-1 blockade increased T cell 
infiltration, leading to superior responses to anti-PD-1 therapies in this tumor type [62]. Likewise, we found that Gal-
1 secretion by tumor-driven γδ T cells contributes to tumor progression by linking commensal microbiota, systemic 
inflammation, and unremitted immunosuppression [63]. 
In addition to the broad immune inhibitory mechanisms, Gal-1 also contributes to tumor growth and progression 
by favoring the generation of tumor-associated blood vessels. We found that Gal-1 promotes vascularization through 
direct association with the complex N-glycans present on the vascular endothelial growth factor (VEGF) type 2 receptor 
(VEGFR2). This pro-angiogenic program is triggered under hypoxic conditions, which up-regulate Gal-1 expression in 
tumor cells [64] and induce changes in VEGFR2 glycosylation characterized by high frequency of complex branched 
N-glycans and low levels of α2,6 sialylation [65]. We found that Gal-1 blockade successfully counteracted resistance to 
anti-VEGF treatment by co-opting the VEGFR2 signaling pathway in different tumor models including mouse Lewis 
lung carcinoma and EL-4 thymic lymphoma [65]. Moreover, antibody-mediated Gal-1 neutralization promoted vessel 
normalization and influx of CD8+ T lymphocytes in different tumor types [65] (Figure 3). Interestingly, in melanoma 
patients treated with anti-VEGF (bevacizumab) and anti-CTLA-4 (ipilimumab), circulating Gal-1 levels are associated 
with a poor clinical outcome, while circulating anti-Gal-1 autoantibodies correlates with clinical response [66]. Thus, Gal-
1 serves as a novel glyco-checkpoint that controls immune and vascular signaling programs and an attractive therapeutic 
target in various cancer types including melanoma, Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), Kaposi’s 
sarcoma, lung, breast, kidney, pancreatic, and prostate carcinomas, glioblastoma and neuroblastoma [58]. Thus, Gal-1 
blockade, either alone or in combination, represents a promising immune therapeutic strategy to treat advanced stage and 
refractory tumors. 
Gal-1: a key regulator of the metastatic cascade
Metastasis is a multistage program through which cancer cells detach from the tissue of origin, migrate through blood or 
lymphatic circulation and colonize a secondary organ [67], [68]. Besides serving as local regulators of immune responses, 
galectin-glycan interactions have emerged as key players of the metastatic cascade, influencing tumor cell migration, 
survival in the circulation, dissemination, and colonization of metastatic organs. Accordingly, Gal-1 can regulate cell-
cell and cell-matrix interactions, a process associated with invasiveness and metastasis in several human tumors [69]. 
Gal-1 also increases adhesion of cells to the extracellular matrix (ECM) by interacting with laminin and fibronectin 
via glycosylation-dependent mechanisms [70–72], and it promotes homotypic and heterotypic aggregation of cancer 
cells [73, 74]. In oral squamous cell carcinoma (OSCC), Gal-1 expression in cancer-associated stroma correlated with 
poor prognosis [75] and promoted tumor invasion by up-regulating metalloproteinase (MMP)-2 and -9 and increasing 
the number and length of filopodia on tumor cells [76]. Additionally, Gal-1 expression is up-regulated by stromal cells 
in invasive breast carcinoma patients when compared with in situ carcinomas [77]. Furthermore, Gal-1 induces up-
regulation of mesenchymal markers and down-regulation of E-cadherin in hepatocellular carcinoma cell lines, promoting 
transition from epithelial morphology toward a fibroblastic mesenchymal phenotype [78]. In addition, studies in gastric 
cancer cells found that high Gal-1 expression levels in cancer-associated fibroblasts (CAFs) up-regulate the expression 
of β1-integrin, inducing cancer cell migration and invasion [79], and promoted epithelial-to-mesenchymal transition 
(EMT) via the non-canonical activation of the Hedgehog pathway [80]. Moreover, in human pancreatic cancer cells, 
Gal-1 induced up-regulation of genes associated with migration and invasion and facilitated EMT through nuclear factor 
kappa B (NF-κB) transcriptional regulation, thus influencing liver metastases [60, 81]. The pro-metastatic activity of 
Gal-1 was also observed in metastatic castration-resistant prostate cancer cell lines, where silencing of this lectin led to 
inhibition of migration and invasion via suppression of Akt and androgen receptor (AR) signaling [82]. Moreover, Gal-1 
has also been identified as a key effector of tropomyosin receptor kinase–mediated invasiveness and migration in human 
neuroblastoma cell lines [83], highlighting diverse mechanisms underlying the pro-metastatic role of this lectin in tumor 
microenvironments.
In addition to the extracellular roles of Gal-1, this lectin has an important intracellular role in cancer by sustaining 
proliferative signals through specific interactions with oncogenic RAS, a well-known cancer driver gene mutated in several 
tumors. Constitutive activation of HRAS, KRAS, and NRAS proteins promotes continuous proliferation in different 
cancer types [84]. In this setting, Gal-1 facilitates RAS membrane anchorage and activation, thereby sustaining tumor cell 
proliferation [85, 86]. On the other hand, the interaction between Gal-1 and RAS in lung cancer leads to chemoresistance 
and tumor progression through the up-regulation of p38, cyclooxygenase-2 and extracellular regulated kinase (ERK) 
pathways [87]. Thus, Gal-1 association with oncogenic proteins, transcription factors, cell adhesion molecules and distinct 
signaling pathways can have an effect on the invasion, dissemination and colonization of cancer cells, emphasizing the 
relevance of Gal-1 blockade to control tumor progression and metastasis. 
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Gal-1: a potential therapeutic agent for autoimmune and chronic inflammatory 
diseases
Autoimmune diseases include a wide range of chronic inflammatory disorders generated by the interruption of immune 
tolerance and homeostatic mechanisms. Both genetic and environmental factors play key roles in the development of 
autoimmune and chronic inflammatory diseases. A deeper understanding of the cellular and molecular mechanisms 
underlying these immune-mediated disorders could lead to the development of new and more effective immunomodulatory 
therapies. Through interaction with glycosylated receptors on immune cells, Gal-1 exerts broad immunoregulatory 
functions promoting resolution of autoimmune inflammation [88]. The mechanisms underlying Gal-1 function involve 
selective deletion of Th1 and Th17 cells, inhibition of pro-inflammatory cytokines, promotion of tolerogenic DCs, 
expansion of Tregs and induction of M2 macrophage polarization [49,88, 89]. 
The precise description of different mechanisms underlying the immunoregulatory effects of different members of 
the galectin family in autoimmune inflammation has been reviewed recently [90]. In this section, we will focus on the 
role of Gal-1 in regulating immune tolerance and suppressing inflammation in different models of autoimmune disease. 
The immunosuppressive properties of Gal-1 have been evaluated in several diseases and experimental models of chronic 
inflammation and autoimmunity, including experimental autoimmune encephalomyelitis (EAE) [49], collagen-induced 
arthritis (CIA) [91, 92], Sjögren’s syndrome [93], 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis [94], celiac 
disease [88], experimental autoimmune uveitis (EAU) [95, 96], experimental autoimmune diabetes [97, 98], experimental 
autoimmune orchitis (EAO) [99] and allergic airway inflammation [100].
Multiple Sclerosis
Multiple Sclerosis (MS) is a chronic progressive brain and spinal cord degenerative disease characterized by the 
demyelination and inflammation of the central nervous system (CNS) [101, 102]. Gal-1 demonstrated immunomodulatory 
activity on experimental autoimmune encephalomyelitis (EAE), an animal model that recapitulates many of the clinical, 
histopathological, and immunological manifestations of MS [103, 104]. The resulting pathology can range from acute 
muscular paralysis episodes to chronic recurrent neurological processes leading to a general motor disability [105]. Th1 
and Th17 lymphocyte subpopulations play key pathogenic roles in the autoimmune process underlying MS and EAE 
[106, 107]. It has been postulated that Th17 cells have a critical role in the initial stage of this disease, whereas IFN-γ-
secreting Th1 cells are more important in later stages of autoimmune neuroinflammation [108]. In fact, myelin-specific 
infiltrating Th17 and Th1 cells determine where CNS inflammation occurs [109]. Brain tissue of MS patients displays an 
increased proportion of Th17 lymphocytes and elevated levels of IL-17A in comparison with healthy controls [106]. We 
studied the role of Gal-1 in EAE by immunization of mice lacking this protein (Lgals1-/-) with myelin-oligodendrocyte 
glycoprotein (MOG)35–55 peptide. Lack of endogenous Gal-1 resulted in greater disease severity as compared to wild-
type (WT) mice [49]. Mice devoid of Gal-1 showed a more pronounced area of demyelination in spinal cord sections, 
increased frequency of antigen-specific Th1 and Th17 cells in the spleen, as well as a more vigorous antigen-specific 
proliferative T-cell response [49]. Accordingly, EAE mice treated daily with recombinant Gal-1 (rGal-1) from day 3 
to 9 after immunization showed a decrease in clinical severity score [49]. We found that Gal-1 exerts its function by 
limiting the frequency of antigen-specific IL-17- and IFN-γ-producing CD4+ T cells as a result of selective apoptosis 
due to differential glycosylation of these immune cell populations [49] (Figure 3). In addition to the ability of Gal-1 
to control T cell physiology, we found that this lectin instructs DCs to differentiate toward a tolerogenic profile. Gal-1-
conditioned DCs acquired a regulatory signature characterized by IL-27 production and ability to induce IL-10-producing 
type-1 regulatory T (Tr1) cells [56]. Supporting these findings, Lgals1-/- mice injected with MOG35-55 showed a decrease in 
tolerogenic DCs and Tregs in comparison to WT mice [110]. Interestingly, a significant increase in Gal-1 expression has 
been reported during the peak and resolution phases of EAE [56], similar to the expression pattern documented for other 
inhibitory signals such as PD-L1 and its receptor PD-1 [111]. In addition, within the CNS, Gal-1 was mainly expressed 
by astrocytes during the resolution phase of EAE. Astrocyte-derived Gal-1 acts directly on microglia cells via interaction 
with core 2 O-glycans on CD45 phosphatase, changing the functional pattern of these cells from a pro-inflammatory M1 
toward an anti-inflammatory M2 phenotype, which prevented inflammation-induced neurodegeneration [112] (Figure 
3). Thus, Gal-1 triggers tolerogenic circuits within the CNS and peripheral lymphoid organs that control the severity of 
autoimmune neuroinflammation.
Rheumatoid Arthritis
Rheumatoid arthritis (RA) involves a chronic inflammation of synovial joints leading to cartilage destruction and 
bone erosion. Induction of autoantibodies, activation of resident fibroblasts, and expansion of activated autoreactive 
lymphocytes, macrophages, and plasma cells are typical hallmarks of this disease [113]. These innate and adaptive 
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immune cells proliferate abnormally, invading both cartilage and bone and inducing increased levels of pro-inflammatory 
cytokines and MMPs that promote the activation of osteoclasts [114]. We assessed the preventive and therapeutic effects 
of Gal-1 in a murine model of CIA by means of gene and protein therapy strategies (Figure 3). Mice were immunized with 
type-II collagen to elicit cellular and humoral arthritogenic responses [115, 116]. Daily injections of recombinant Gal-1 
or transfer of genetically-modified fibroblasts secreting high levels of this lectin, reduced the frequency of circulating 
anti-collagen immunoglobulins, particularly IgG2a in mice with CIA. The mechanism underlying this effect involved 
a shift toward a Th2-like profile, with decreased IFN-γ and increased IL-5 production [91]. Further studies contributed 
to elucidate the role of Gal-1 in RA by showing that Lgals1-/- mice had increased susceptibility to CIA, showing more 
vigorous T cell proliferation and augmented expression of IL-17 and IL-22 [92]. In RA patients, the concentration of Gal-
1 in synovial fluid decreased significantly compared to healthy controls, even though plasmatic levels were comparable 
[117]. Likewise, we found a decreased expression of this lectin in synovial tissue of juvenile idiopathic arthritis patients 
[118]. Moreover, in a local cohort of RA patients, we found considerably higher levels of serum Gal-1 correlating with 
systemic inflammation compared to healthy individuals [89], suggesting differences in local versus systemic regulation of 
this lectin during the course of the disease. Thus, Gal-1 controls arthritogenic inflammation by restoring T cell homeostasis 
and modulating cytokine production.
Sjögren’s syndrome
Sjögren’s syndrome is characterized by lymphocytic infiltration of exocrine glands and the presence of different 
autoantibodies. In contrast to CIA and EAE models, where mice were immunized with arthritogenic and encephalitogenic 
peptides, mice lacking Gal-1 or complex branched N-glycans developed spontaneous age-dependent sialadenitis 
resembling Sjögren’s syndrome manifestations [93]. Lack of Gal-1 disrupted tolerogenic circuits and enhanced T cell 
activation and recruitment to the salivary glands. We demonstrated that aged Lgals1-/- mice had lower expression of PD-
L1 in salivary gland cells and increased recruitment of IFN-γ-producing PD-1+ CD8+ T cells to this organ. Moreover, 
Gal-1-deficient mice showed higher frequency of DCs with immunogenic capacity [93]. We verified these findings in 
nonobese diabetic (NOD) mice, a well-established mouse model for Sjögren’s-like syndrome. Administration of rGal-1 to 
NOD mice rescued the autoimmune phenotype showing a significant reduction of CD45+ cells within the salivary glands. 
Accordingly, labial biopsies from primary Sjögren’s syndrome patients showed reduced Gal-1 expression concomitant 
with a higher number of infiltrating CD8+ T cells [93]. These findings demonstrate that endogenous Gal-1 plays a key role 
in preventing age-dependent development of spontaneous autoimmunity (Figure 3).
Inflammatory bowel disease
Inflammatory bowel diseases (IBD) constitute a group of multifactorial chronic disorders that affect the digestive 
tract, such as Crohn’s disease (CD) and ulcerative colitis (UC). These disorders are characterized by a dysregulation 
of mucosal immune homeostasis, due to defects in tolerance induction against commensal microbiota or excessive 
activation of effector immune responses [119]. The 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis mouse 
model recapitulates several features of IBD. In this model, the TNBS hapten is delivered into the mouse colonic lumen, 
eliciting an inflammatory immune response in the gut. The broad tolerogenic responses of Gal-1 prompted speculation 
on its potential regulatory role in the control of colitogenic immune responses in the inflamed gut. Administration of 
rGal-1 in this model resulted in an increased number of apoptotic T cells in the colonic lamina propria and a decreased 
frequency of Th1 cytokines in comparison with untreated mice [120]. Moreover, this lectin also maintained intestinal 
tissue homeostasis through the control of epithelial cell viability and regulation of epithelial-derived immunoregulatory 
cytokines [121] (Figure 3).  Future studies should explore the exact role of this lectin and its glycosylated ligands on 
intestinal immune cell populations.
Celiac disease
Celiac disease is a T-cell mediated disorder where chronic intestinal inflammation occurs as a result of immune responses 
to wheat gluten peptides. This dysregulated immune response has multifactorial etiology and up to now, the only effective 
treatment known is strict adherence to gluten-free diet [122]. We demonstrated an increased expression of Gal-1 in 
duodenal biopsies of celiac disease patients after a lifelong gluten-free diet, compared to patients who did not take this 
diet [88]. These findings suggested that this lectin might contribute to the resolution of chronic inflammation in response 
to gluten withdrawal. Moreover, Gal-1 could be considered as a potential biomarker for the follow-up of celiac disease 
patients [88]. Future studies should be aimed at analyzing the role of endogenous Gal-1 or exogenous rGal-1 administration 
in mouse models of celiac disease. 
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Uveitis
Autoimmune uveitis is characterized by an inflammatory response that occurs in the uvea and can adversely affect vision 
leading to blindness [123]. Experimental autoimmune uveitis (EAU) is a mouse model of this intraocular inflammatory 
disease characterized by the inflammation and destruction of the neural retina. The disease is induced by immunization 
with retinal antigens such as interphotoreceptor retinoid binding protein (IRBP) and adjuvants like pertussis toxin (PTX). 
In this model, we demonstrated that the administration of rGal-1 decreased disease severity, mainly by reducing immune 
cell infiltration and shifting the Th1 response towards a Th2 or Treg cell profile [95]. Meanwhile, in the endotoxin-induced 
uveitis (EIU) model, the disease is induced by inoculation with lipopolysaccharide (LPS) in the rat’s paw. Administration 
of rGal-1 to LPS-treated rats attenuated the histopathological manifestations of EIU, suppressing the expression 
of pro-inflammatory cytokines such as IL-6, IL-1β, and monocyte chemotactic protein-1 (MCP-1), thus inhibiting 
polymorphonuclear cells infiltration [96]. Furthermore, in clinical settings, anti-Gal-1 autoantibodies correlated with the 
severity of ocular pathology in autoimmune and infectious uveitis [124]. Further studies should be aimed at analyzing 
the protective role of endogenous Gal-1 in preserving immune privilege in the eye and preventing ocular inflammation.
Diabetes 
In type I diabetes, insulin-producing pancreatic β-cells are destroyed by autoreactive T cells [97]. Gal-1 demonstrated 
an anti-inflammatory role in spontaneous diabetes in NOD mice. This effect was accompanied by downregulation of T 
cell pro-inflammatory response and augmented frequency of Th2 responses, thus preventing hyperglycemia at early and 
subclinical stages [97]. Supporting these findings, patients with type 1 diabetes had lower serum levels of Gal-1 compared 
to healthy controls, mainly due to a reduced secretion of this lectin by monocytes [98] (Figure 3). Whether Gal-1-driven 
programs could link immune, endocrine, and metabolic pathways in diabetic individuals still remains to be elucidated. 
Orchitis
Testicular inflammation and anti-sperm antibodies are the main features of autoimmune orchitis [125]. Given the high 
expression of Gal-1 in Sertoli testicular cells [126], we investigated the possible role of this lectin in autoimmune testicular 
inflammation. In a model of experimental autoimmune orchitis (EAO), we found that Gal-1 expression did not correlate 
with the extent of the inflammatory response. Paradoxically, in this model, Lgals1-/- mice showed a reduction in the 
incidence and severity of the disease. However, when rGal-1 was administered exogenously, inflammation was dampened, 
and clinical symptoms were attenuated similarly to other autoimmune inflammation models [99]. These results highlight 
the dual role of endogenous versus exogenous Gal-1 in this particular experimental model. Further studies should be 
aimed at dissecting innate and adaptive components differentially regulated by exogenous and endogenous Gal-1 in 
autoimmune testicular inflammation.
Allergic Airway Inflammation
Allergic airway inflammation is characterized by elevated recruitment of eosinophils to the lung and increased activation 
of antigen-specific Th2 responses. Murine models resembling allergic asthma involve acute or chronic exposure to 
ovalbumin (OVA). We evaluated the relevance of the Gal-1-glycan axis in this model. An immunohistochemical analysis 
revealed recruitment of Gal-1-expressing inflammatory eosinophils to the inflamed lungs [100]. Interestingly, Gal-1 
expression was up-regulated in the epithelial cells, smooth muscle cells and endothelial cells of the lungs and within the 
extracellular space as a result of allergen exposure. Recombinant Gal-1 inhibited eosinophil migration through specific 
recognition of LacNAc residues on the surface of these cells. Moreover, in vivo studies showed augmented eosinophil 
and T cell recruitment to the airways in allergen-exposed Lgals1-/- compared to WT mice. Thus, allergen-challenged 
Lgals1-/- mice exhibited airway hyperresponsiveness that could be attributed to a lack of eosinophilia regulation by 
Gal-1 at inflammation sites [100]. Overall, this study showed an important role for Gal-1 in the resolution of airway 
inflammation through the control of eosinophils’ migratory and functional capacity, opening therapeutic avenues for 
eosinophil-dependent inflammatory responses (Figure 3).
Immune-related failing pregnancies
The elevated amounts of Gal-1 during gestation in different species and its high sensitivity to hormonal regulation [127, 
128], prompted us to investigate the role of this lectin during pregnancy. Consistent with a marked decrease in Gal-1 
expression during failing pregnancies, Lgals1-/- female mice showed higher rates of fetal loss compared to WT mice in 
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allogeneic mating. Treatment with rGal-1 prevented fetal loss and restored tolerance through mechanisms involving 
expansion of IL-10-secreting Treg cells in vivo [129]. Supporting these findings, increased frequency of circulating anti-
Gal-1 autoantibodies were detected in sera from women with spontaneous recurrent abortions compared to fertile women 
[130]. Interestingly, Gal-1 also controls sperm fertilizing activity [131], suggesting diverse roles for this lectin during 
mammalian reproduction and gestation.
Figure 3. Contrasting roles of Gal-1 in autoimmunity and cancer. On the right, several immunosuppressive effects that 
Gal-1 exerts within the tumor microenvironment are illustrated, including induction of CD8+ T cell apoptosis, expansion 
of immunosuppressive Tregs, differentiation of tolerogenic DCs, induction of macrophage polarization from a pro-
inflammatory M1 toward an anti-inflammatory M2 profile, and promotion of aberrant angiogenesis. Gal-1 blockade 
triggers an effective T cell mediated anti-tumor response and control of tumor growth. On the left, the beneficial functions 
underlying the administration of rGal-1 in autoimmune diseases are outlined, including selective death of Th1 and Th17 
lymphocytes, inhibition of pro-inflammatory cytokines, differentiation of tolerogenic DCs leading to expansion of Tr1 
cells, and promotion of Treg cell expansion. Thus, administration of exogenous rGal-1 would favor the resolution of 
inflammatory and autoimmune processes. Created with BioRender.com
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Concluding Remarks and Future Perspectives
In this review, we discussed the multifunctional roles of Gal-1, an endogenous immunomodulatory β-galactoside binding 
protein, in cancer and autoimmune inflammation. Through recognition of terminal LacNAc residues present in complex 
branched N-glycans and core-2 O-glycan structures, this lectin recalibrates innate and adaptive responses by modulating 
the survival, activation, trafficking, and differentiation of immune cells. Expression of Gal-1 during peak and resolution 
phases of inflammatory responses contributes to restoring immune homeostasis by blunting exacerbated immune responses 
through induction of glycosylation-dependent tolerogenic circuits. Accordingly, dysregulation of Gal-1 expression and/or 
its glycosylated ligands contribute to the establishment and perpetuation of pathologic conditions.
On the one hand, interruption of Gal-1-glycan interactions leads to exacerbation of inflammatory and autoimmune 
responses. It has been demonstrated in a wide range of experimental models of autoimmune diseases that the absence 
of Gal-1 aggravates the clinical severity of the disease [49, 56, 92, 93, 112]. In this regard, we recently found that 
aged Lgals1-/- mice spontaneously develop a Sjögren’s-like syndrome [93], providing clear-cut evidence of the central 
role of endogenous Gal-1 in the control of immune homeostatic programs. This effect was further validated by the 
broad immunomodulatory activity of exogenous rGal-1 in a broad range of autoimmune experimental models [90]. 
Interestingly, augmented T cell-dependent inflammatory responses have also been observed in mice lacking the Mgat5 
glycosyltransferase, responsible for generating galectin ligands [17]. These findings place the Gal-1-glycan axis at the 
center of the scene of immune tolerance and homeostasis, highlighting a potential therapeutic target for T cell-dependent 
autoimmune inflammation. Since current therapies in autoimmune diseases are not curative and show substantial side 
effects [132], Gal-1-based immunomodulatory agonists emerge as potential immunomodulators to recalibrate immunity 
and restore immunological homeostasis. 
On the other hand, in the context of neoplastic diseases, Gal-1 favors tumor growth and metastasis by fostering 
immunosuppression and angiogenesis. Since our initial discovery showing that melanoma cells evade T cell-mediated 
antitumor responses by secreting Gal-1 [48], this paradigm has been extended to a broad range of tumors including lung 
adenocarcinoma, Hodgkin lymphoma, pancreatic adenocarcinoma, glioblastoma, neuroblastoma, breast adenocarcinoma, 
chronic lymphocytic leukemia and others [58]. Additionally, this lectin stimulates the generation of aberrant vascular 
networks at sites of tumor growth and facilitates tumor-stroma interactions, favoring dissemination, colonization, and 
metastatic disease [65, 133]. Remarkably, this endogenous lectin confers resistance to different treatments including anti-
angiogenic therapy, immunotherapy, chemotherapy, radiotherapy, and targeted therapies [134]. Collectively, these results 
underscore the potential therapeutic value of Gal-1 blockade, using neutralizing monoclonal antibodies, synthetic or 
natural glycans or antagonistic peptides [135], either alone or in combination with other therapeutic modalities for treating 
a wide range of tumors. Future basic and clinical research is awaited to validate galectin-based therapeutic strategies and 
translate these findings from bench to bedside and back again.
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